306 related articles for article (PubMed ID: 33053330)
1. CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8
Braun M; Aguilera AR; Sundarrajan A; Corvino D; Stannard K; Krumeich S; Das I; Lima LG; Meza Guzman LG; Li K; Li R; Salim N; Jorge MV; Ham S; Kelly G; Vari F; Lepletier A; Raghavendra A; Pearson S; Madore J; Jacquelin S; Effern M; Quine B; Koufariotis LT; Casey M; Nakamura K; Seo EY; Hölzel M; Geyer M; Kristiansen G; Taheri T; Ahern E; Hughes BGM; Wilmott JS; Long GV; Scolyer RA; Batstone MD; Landsberg J; Dietrich D; Pop OT; Flatz L; Dougall WC; Veillette A; Nicholson SE; Möller A; Johnston RJ; Martinet L; Smyth MJ; Bald T
Immunity; 2020 Oct; 53(4):805-823.e15. PubMed ID: 33053330
[TBL] [Abstract][Full Text] [Related]
2. Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8
Weulersse M; Asrir A; Pichler AC; Lemaitre L; Braun M; Carrié N; Joubert MV; Le Moine M; Do Souto L; Gaud G; Das I; Brauns E; Scarlata CM; Morandi E; Sundarrajan A; Cuisinier M; Buisson L; Maheo S; Kassem S; Agesta A; Pérès M; Verhoeyen E; Martinez A; Mazieres J; Dupré L; Gossye T; Pancaldi V; Guillerey C; Ayyoub M; Dejean AS; Saoudi A; Goriely S; Avet-Loiseau H; Bald T; Smyth MJ; Martinet L
Immunity; 2020 Oct; 53(4):824-839.e10. PubMed ID: 33053331
[TBL] [Abstract][Full Text] [Related]
3. IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma.
Chauvin JM; Ka M; Pagliano O; Menna C; Ding Q; DeBlasio R; Sanders C; Hou J; Li XY; Ferrone S; Davar D; Kirkwood JM; Johnston RJ; Korman AJ; Smyth MJ; Zarour HM
Clin Cancer Res; 2020 Oct; 26(20):5520-5533. PubMed ID: 32591463
[TBL] [Abstract][Full Text] [Related]
4. Integrated single-cell and bulk sequencing analyses with experimental validation identify the prognostic and immunological implications of CD226 in pan-cancer.
Ma P; Sun W
J Cancer Res Clin Oncol; 2023 Nov; 149(16):14597-14617. PubMed ID: 37580402
[TBL] [Abstract][Full Text] [Related]
5. CD226
Jin HS; Ko M; Choi DS; Kim JH; Lee DH; Kang SH; Kim I; Lee HJ; Choi EK; Kim KP; Yoo C; Park Y
Cancer Immunol Res; 2020 Jul; 8(7):912-925. PubMed ID: 32265229
[TBL] [Abstract][Full Text] [Related]
6. Increased Soluble CD226 in Sera of Patients with Cutaneous T-Cell Lymphoma Mediates Cytotoxic Activity against Tumor Cells via CD155.
Takahashi N; Sugaya M; Suga H; Oka T; Kawaguchi M; Miyagaki T; Fujita H; Inozume T; Sato S
J Invest Dermatol; 2017 Aug; 137(8):1766-1773. PubMed ID: 28395975
[TBL] [Abstract][Full Text] [Related]
7. TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.
Chauvin JM; Pagliano O; Fourcade J; Sun Z; Wang H; Sander C; Kirkwood JM; Chen TH; Maurer M; Korman AJ; Zarour HM
J Clin Invest; 2015 May; 125(5):2046-58. PubMed ID: 25866972
[TBL] [Abstract][Full Text] [Related]
8. CD155/CD226-interaction impacts on the generation of innate CD8(+) thymocytes by regulating iNKT-cell differentiation.
Georgiev H; Ravens I; Shibuya A; Förster R; Bernhardt G
Eur J Immunol; 2016 Apr; 46(4):993-1003. PubMed ID: 26689152
[TBL] [Abstract][Full Text] [Related]
9. Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Lepletier A; Madore J; O'Donnell JS; Johnston RL; Li XY; McDonald E; Ahern E; Kuchel A; Eastgate M; Pearson SA; Mallardo D; Ascierto PA; Massi D; Merelli B; Mandala M; Wilmott JS; Menzies AM; Leduc C; Stagg J; Routy B; Long GV; Scolyer RA; Bald T; Waddell N; Dougall WC; Teng MWL; Smyth MJ
Clin Cancer Res; 2020 Jul; 26(14):3671-3681. PubMed ID: 32345648
[TBL] [Abstract][Full Text] [Related]
10. CD226 identifies functional CD8
Huang H; Huang Z; Ge J; Yang J; Chen J; Xu B; Wu S; Zheng X; Chen L; Zhang X; Jiang J
Front Immunol; 2023; 14():1150803. PubMed ID: 37056782
[TBL] [Abstract][Full Text] [Related]
11. BCL9 regulates CD226 and CD96 checkpoints in CD8
Feng M; Wu Z; Zhou Y; Wei Z; Tian E; Mei S; Zhu Y; Liu C; He F; Li H; Xie C; Jin J; Dong J; Yang D; Yu K; Qian J; Lambrechts D; Wang MW; Zhu D
Signal Transduct Target Ther; 2021 Aug; 6(1):313. PubMed ID: 34417435
[TBL] [Abstract][Full Text] [Related]
12. TIGIT and PD1 Co-blockade Restores ex vivo Functions of Human Tumor-Infiltrating CD8
Ge Z; Zhou G; Campos Carrascosa L; Gausvik E; Boor PPC; Noordam L; Doukas M; Polak WG; Terkivatan T; Pan Q; Takkenberg RB; Verheij J; Erdmann JI; IJzermans JNM; Peppelenbosch MP; Kraan J; Kwekkeboom J; Sprengers D
Cell Mol Gastroenterol Hepatol; 2021; 12(2):443-464. PubMed ID: 33781741
[TBL] [Abstract][Full Text] [Related]
13. Blocking CD226 Promotes Allogeneic Transplant Immune Tolerance and Improves Skin Graft Survival by Increasing the Frequency of Regulatory T Cells in a Murine Model.
Liu T; Zhang D; Zhang Y; Xu X; Zhou B; Fang L; Zhang Y; Su Y; Jin B; Zhuang R; Guo S
Cell Physiol Biochem; 2018; 45(6):2338-2350. PubMed ID: 29550821
[TBL] [Abstract][Full Text] [Related]
14. Intranodal interaction with dendritic cells dynamically regulates surface expression of the co-stimulatory receptor CD226 protein on murine T cells.
Seth S; Qiu Q; Danisch S; Maier MK; Braun A; Ravens I; Czeloth N; Hyde R; Dittrich-Breiholz O; Förster R; Bernhardt G
J Biol Chem; 2011 Nov; 286(45):39153-63. PubMed ID: 21937446
[TBL] [Abstract][Full Text] [Related]
15. CD226 interaction with CD155 impacts on retention and negative selection of CD8 positive thymocytes as well as T cell differentiation to follicular helper cells in Peyer's Patches.
Danisch S; Qiu Q; Seth S; Ravens I; Dorsch M; Shibuya A; Shibuya K; Förster R; Bernhardt G
Immunobiology; 2013 Feb; 218(2):152-8. PubMed ID: 22429743
[TBL] [Abstract][Full Text] [Related]
16. TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment.
Kawashima S; Inozume T; Kawazu M; Ueno T; Nagasaki J; Tanji E; Honobe A; Ohnuma T; Kawamura T; Umeda Y; Nakamura Y; Kawasaki T; Kiniwa Y; Yamasaki O; Fukushima S; Ikehara Y; Mano H; Suzuki Y; Nishikawa H; Matsue H; Togashi Y
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34795004
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneous expression of the adhesion receptor CD226 on murine NK and T cells and its function in NK-mediated killing of immature dendritic cells.
Seth S; Georgoudaki AM; Chambers BJ; Qiu Q; Kremmer E; Maier MK; Czeloth N; Ravens I; Foerster R; Bernhardt G
J Leukoc Biol; 2009 Jul; 86(1):91-101. PubMed ID: 19380711
[TBL] [Abstract][Full Text] [Related]
18. Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112).
Tahara-Hanaoka S; Shibuya K; Onoda Y; Zhang H; Yamazaki S; Miyamoto A; Honda S; Lanier LL; Shibuya A
Int Immunol; 2004 Apr; 16(4):533-8. PubMed ID: 15039383
[TBL] [Abstract][Full Text] [Related]
19. Combinatorial immunotherapy induces tumor-infiltrating CD8
Van Braeckel-Budimir N; Dolina JS; Wei J; Wang X; Chen SH; Santiago P; Tu G; Micci L; Al-Khami AA; Pfister S; Ram S; Sundar P; Thomas G; Long H; Yang W; Potluri S; Salek-Ardakani S
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34903555
[TBL] [Abstract][Full Text] [Related]
20. Binding mode of the side-by-side two-IgV molecule CD226/DNAM-1 to its ligand CD155/Necl-5.
Wang H; Qi J; Zhang S; Li Y; Tan S; Gao GF
Proc Natl Acad Sci U S A; 2019 Jan; 116(3):988-996. PubMed ID: 30591568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
